Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Melanoma 7Neuroendocrine Tumors 2Multiple Myeloma 2Neoplasms 1Neoplasm Metastasis 1Lymphoma, Follicular 1Lymphoma 1Liver Cirrhosis 1Hepatitis C 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Hepatocellular 1

Interventions

Dexamethasone 168Bortezomib 90Lenalidomide 85Thalidomide 44daratumumab 43pomalidomide 42Melphalan 39Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 12ixazomib 11isatuximab 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5Radiotherapy 4Mycophenolic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × Introns × Clear all
NCT00083551 2015-11-23

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

University of Arkansas

Phase 3 Completed
668 enrolled 7 charts
Plasma cell

Multiple Myeloma, Neoplasms

NCT00002556 2013-05-31

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Completed
312 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡